PROSOMNUS INC (OSA) Stock Price, Forecast & Analysis
USA - NASDAQ:OSA - US50535E1082 - Common Stock
OSA Key Statistics, Chart & Performance
The current stock price of OSA is 0.47 USD. In the past month the price decreased by -29.09%. In the past year, price decreased by -90.8%.
OSA Latest News, Press Relases and Analysis
OSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.17 | 227.29B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.82 | 196.99B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.81 | 152.16B | ||
| SYK | STRYKER CORP | 27.5 | 138.48B | ||
| IDXX | IDEXX LABORATORIES INC | 54.71 | 55.19B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.58 | 50.67B | ||
| RMD | RESMED INC | 24.69 | 35.68B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.94 | 33.40B | ||
| DXCM | DEXCOM INC | 31.22 | 22.77B | ||
| PODD | INSULET CORP | 72.8 | 23.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.81B |
Related stock screener links
About OSA
Company Profile
Prosomnus, Inc. is a medical technology company, which engages in the business of developing, manufacturing, and marketing precision intraoral medical devices. The company is headquartered in Pleasanton, California and currently employs 129 full-time employees. The company went IPO on 2021-06-15. The Company’s intraoral medical devices are engineered to track the treatment plan and anatomy of each patient. Its precision intraoral devices are Food and Drug Administration (FDA)-cleared, patented and covered by commercial medical insurance, Medicare, TRICARE and other Government-sponsored healthcare plans around the world, representing approximately 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide. The Company’s wholly owned subsidiaries include ProSomnus Holdings, Inc. and ProSomnus Sleep Technologies, Inc.
Company Info
PROSOMNUS INC
5675 Gibraltar Dr
Pleasanton CALIFORNIA US
Employees: 129
Phone: 18445375337
PROSOMNUS INC / OSA FAQ
What does OSA do?
Prosomnus, Inc. is a medical technology company, which engages in the business of developing, manufacturing, and marketing precision intraoral medical devices. The company is headquartered in Pleasanton, California and currently employs 129 full-time employees. The company went IPO on 2021-06-15. The Company’s intraoral medical devices are engineered to track the treatment plan and anatomy of each patient. Its precision intraoral devices are Food and Drug Administration (FDA)-cleared, patented and covered by commercial medical insurance, Medicare, TRICARE and other Government-sponsored healthcare plans around the world, representing approximately 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide. The Company’s wholly owned subsidiaries include ProSomnus Holdings, Inc. and ProSomnus Sleep Technologies, Inc.
What is the current price of OSA stock?
The current stock price of OSA is 0.47 USD. The price decreased by -10.29% in the last trading session.
What is the dividend status of PROSOMNUS INC?
OSA does not pay a dividend.
What is the ChartMill rating of PROSOMNUS INC stock?
OSA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is PROSOMNUS INC (OSA) expected to grow?
The Revenue of PROSOMNUS INC (OSA) is expected to grow by 41.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is PROSOMNUS INC worth?
PROSOMNUS INC (OSA) has a market capitalization of 8.17M USD. This makes OSA a Nano Cap stock.
OSA Technical Analysis
OSA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OSA. OSA may be in some trouble as it scores bad on both profitability and health.
OSA Financial Highlights
Over the last trailing twelve months OSA reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS decreased by -28.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.44% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OSA Forecast & Estimates
7 analysts have analysed OSA and the average price target is 2.55 USD. This implies a price increase of 442.55% is expected in the next year compared to the current price of 0.47.
For the next year, analysts expect an EPS growth of -101.05% and a revenue growth 41.66% for OSA